腹腔镜肝切除术治疗原发性肝癌患者应用右美托咪定复合布托啡诺术后镇痛效果研究*

doi:10.3969/j.issn.1672-5069.2023.06.033

摘要/Abstract

摘要： 目的探讨应用右美托咪定(DEX)复合布托啡诺(BUT)对腹腔镜肝切除术(LH)治疗的原发性肝癌(PLC)患者麻醉苏醒和术后疼痛的影响。方法 2019年1月～2022年10月我院诊治的PLC患者74例,随机分为对照组37例和观察组37例,均择期行LH治疗。在术后镇痛时,分别采取舒芬太尼(SUF)复合BUT或Dex复合BUT镇痛泵持续静脉泵入。采用疼痛视觉模拟评分(VAS)评价术后疼痛程度,采用Ramsay镇静评分^【11】量表评价术后镇痛效果。结果观察组手术时间和麻醉时间分别为(210.4±20.2)min和(228.7±30.6)min,与对照组【分别为(208.1±28.3)min和(226.5±32.9)min】比,差异无统计学意义(P＞0.05),而观察组自主呼吸恢复时间和苏醒时间分别为(15.5±3.1) min和(18.2±4.3)min,均显著短于对照组【分别为(20.3±4.9)min和(22.9±4.9)min,P＜0.05】;在术后4 h、24 h和48 h,观察组VAS评分分别为(2.3±0.5)分、(1.1±0.3)分和(0.9±0.2)分,与对照组【分别为(2.5±0.6)分、(1.2±0.3)分和(1.0±0.3)分】比,差异均无统计学意义(P＞0.05);观察组Ramsay镇痛评分分别为(2.4±0.5)分、(2.8±0.6)分和(3.1±0.7)分,均显著高于对照组【分别为(1.5±0.3)分、(1.9±0.4)分和(2.2±0.5)分,P＜0.05】;观察组不良反应发生率为5.4%,显著低于对照组的21.6%(P＜0.05)。结论在行LH治疗的PLC患者术后应用DEX复合BUT镇痛能够显著提高镇痛效果,可能有利于术后康复。

关键词: 原发性肝癌, 腹腔镜肝癌切除术, 右美托咪定, 布托啡诺, 镇痛

Abstract: Objective The aim of this study was to observe the post-operational analgesia effects of dexmedetomidine (DEX) and butorphanol (BUT) combination in patients with primary liver cancer (PLC) after laparoscopic hepatectomy (LH). Methods 74 patients with PLC were enrolled in our hospital between January 2019 and October 20222, and were randomly divided into control (n=37) and observation group (n=37). All patients underwent selective LH, and post-operationally, the patients in the control and in the observation group were intravenously pumping in sufentanil (SUF) and BUT, and Dex and BUT combination for analgesia. The pain and sedation after surgery were evaluated by visual analogue scale (VAS) and Ramsay sedation. Results The operation times and anesthesia times between the observation and the control group were (210.4±20.2) min and (228.7±30.6) min vs. (208.1±28.3) min and (226.5±32.9) min (P>0.05), while the recovery of spontaneous breathing and awakening time in the observation group were(15.5±3.1) min and (18.2±4.3)min, both significantly shorter than [(20.3±4.9)min and (22.9±4.9)min, P＜0.05] in the control; at 4 h, 24 h and 48 h post-operationally, the VAS scores in the observation group were (2.3±0.5), (1.1±0.3) and (0.9±0.2), not significantly different compared to [(2.5±0.6), (1.2±0.3) and (1.0±0.3), respectively, P＞0.05] in the control; the Ramsay scores in the observation group were (2.4±0.5), (2.8±0.6) and (3.1±0.7), all significantly greater than [(1.5±0.3), (1.9±0.4) and (2.2±0.5), respectively, P＜0.05] in the control; the incidence of untoward effects in the observation group was 5.4%, much lower than 21.6%(P＜0.05) in the control. Conclusion The application of DEX and BUT combination after LH could obviously improve analgesia and relieve pain, which might improve the recovery of patients with PLC.

Key words: Hepatoma, Laparoscopic hepatectomy, Dexmedetomidine, Butorphanol, Analgesia

楼鹏, 邓继红, 严铭一. 腹腔镜肝切除术治疗原发性肝癌患者应用右美托咪定复合布托啡诺术后镇痛效果研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 899-902.

Lou Peng, Deng Jihong, Yan Mingyi. Post-operational alanalgesia of dexmedetomidine and butorphanol combination in patients with primary liver cancer after laparoscopic hepatectomy[J]. Journal of Practical Hepatology, 2023, 26(6): 899-902.

参考文献

[1] Polidoro MA, Mikulak J, Cazzetta V, et al. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol, 2020,26(33):4900-4918.
[2] Yang WS, Zeng XF, Liu ZN, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br J Nutr, 2020,124(3):330-340.
[3] Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer, 2021,148(5):1051-1065.
[4] Delvecchio A, Conticchio M, Ratti F, et al. Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score based analysis. Surg Endosc, 2021,35(7):3642-3652.
[5] 吴丹,夏燕飞,杨晓明,等. 急性疼痛管理在胸科手术中镇痛的效果评价. 中华医学杂志,2020,100(38):3010-3013.
[6] Tasbihgou SR, Barends CRM, Absalom AR. The role of dexmedetomidine in neurosurgery. Best Pract Res Clin Anaesthesiol, 2021,35(2):221-229.
[7] Ji J, Lin W, Vrudhula A, et al. Molecular interaction between butorphanol and κ-opioid receptor. Anesth Analg, 2020,131(3):935-942.
[8] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21(3):145-151.
[9] Rosas S, Paço M, Lemos C, et al. Comparison between the visual analog scale and the numerical rating scale in the perception of esthetics and pain. Int Orthod,2017,15(4):543-560.
[10] Li L, Xiao PH, Yao XF, et al. Evaluation of the effect of bispectral index monitoring combined with Ramsay score on sedation depth. World Clin Med,2016,10(23):73-74.
[11] Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer, 2022,161(1):108-118.
[12] Cabasag CJ, Vignat J, Laversanne M, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol, 2022,77(6):1598-1606.
[13] Yoshida H, Taniai N, Yoshioka M, et al. Currentstatus of laparoscopic hepatectomy. J Nippon Med Sch, 2019,86(4):201-206.
[14] 江现强,俞渊,陆世锋. 腹腔镜肝叶切除术常见并发症的危险因素分析及临床处理. 实用肝脏病杂志,2017,20(2):215-218.
[15] Yadav J, Regmi MC, Basnet P, et al. Butorphanol inlabour analgesia. JNMA J Nepal Med Assoc, 2018,56(214):940-944.
[16] Gültiken N, Gürler H, Yarım GF, et al. Antioxidant and analgesic potential of butorphanol in dogs undergoing ovariohysterectomy. Theriogenology, 2022,190(1):1-7.
[17] Lee W, Gao X, Tang J, et al. Postoperative sufentanil intravenous patient-controlled analgesia within the first 24 hours: a retrospective study. Ann Palliat Med,2020,9(6):3932-3937.
[18] Sridharan K, Sivaramakrishnan G. Comparison of fentanyl, remifentanil, sufentanil and alfentanil in combination with propofol for general anesthesia: a systematic review and meta-analysis of randomized controlled Trials. Curr Clin Pharmacol,2019,14(2):116-124.
[19] Mei B, Li J, Zuo Z. Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy via central α2A adrenoceptor. Brain Behav Immun, 2021,91(1):296-314.
[20] Kaye AD, Chernobylsky DJ, Thakur P, et al. Dexmedetomidine in enhanced recovery after surgery (ERAS) protocols for postoperative pain. Curr Pain Headache Rep, 2020,24(5):21.
[21] Liu S, Peng P, Hu Y, et al. The effectiveness and safety of intravenous dexmedetomidine of different concentrations combined with butorphanol for post-caesarean section analgesia: A randomized controlled trial. Drug Des Devel Ther, 2021,15(1):689-698.
[22] Du J, Li JW, Jin J, et al. Intraoperative and postoperative infusion of dexmedetomidine combined with intravenous butorphanol patient-controlled analgesia following total hysterectomy under laparoscopy. Exp Ther Med, 2018,16(5):4063-4069.
[23] Wang X, Wang Z, Sun C, et al. Clinicalstudy of dexmedetomidine in combination with butorphanol for the treatment of postoperative traumatic brain injury (TBI). Turk Neurosurg, 2022,7(1):1019-1022.

腹腔镜肝切除术治疗原发性肝癌患者应用右美托咪定复合布托啡诺术后镇痛效果研究^*

Post-operational alanalgesia of dexmedetomidine and butorphanol combination in patients with primary liver cancer after laparoscopic hepatectomy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.
[2]	莫春明, 黄德佳, 韦惠章, 罗江伟. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 887-890.
[3]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[4]	蓝春雨, 范丽琴, 颜状, 王小龙, 朱加猛. 影响肝叶切除术治疗的原发性肝癌患者长期生存的因素分析^*[J]. 实用肝脏病杂志, 2023, 26(5): 698-701.
[5]	陈长广, 肖荣, 王俊. DEB-TACE序贯射频消融治疗原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 706-709.
[6]	程辉, 刘万清, 张琴. 罗哌卡因联合曲安奈德腹横肌平面阻滞在腹腔镜下肝癌切除术患者术后镇痛中的应用价值研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 710-713.
[7]	余波, 余雯雯, 徐敏. 不同浓度七氟醚吸入复合丙泊酚靶控输注麻醉对行肝叶切除治疗的原发性肝癌患者血流动力学和术后认知功能的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 714-717.
[8]	刘莹, 陈东妙, 王从容. 慢性乙型肝炎、乙型肝炎肝硬化和原发性肝癌患者血清腺苷脱氨酶、α-L-岩藻糖苷酶和AFP-L3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 552-555.
[9]	陈钰, 陈斌斌, 赵静, 吴彬彬. MRI联合血清AFP-L3和VEGF水平预测TACE术治疗的原发性肝癌患者预后的价值^*[J]. 实用肝脏病杂志, 2023, 26(4): 556-559.
[10]	石磊, 安梓铭, 冯琴. 联合检测血清AFP、AFP-L3%和PIVKA-II水平早期诊断和判断原发性肝癌患者预后临床价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 404-407.
[11]	林永祝, 史红媛, 穆西虎. 双源CT肝动脉三期扫描和增强灌注扫描诊断肝硬化背景下小原发性肝癌价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 412-415.
[12]	唐亮, 陈曦, 王文高, 董超. TACE联合直线加速器三维适形放疗治疗中晚期原发性肝癌患者近期临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(3): 416-419.
[13]	段海珊, 蒋黎, 田青青, 孔令军, 游忠岚, 何小勤. 原发性肝癌和肝血管瘤患者超声造影表现特点比较^*[J]. 实用肝脏病杂志, 2023, 26(3): 420-423.
[14]	钟欢, 叶伟. 阿伐曲泊帕治疗肝硬化和原发性肝癌患者血小板减少症疗效分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 440-442.
[15]	顾凯, 吴晓晨, 朱逸明. 单次大剂量肝区放射照射治疗原发性肝癌肝区疼痛患者效果研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 270-273.